08/22/2024
7:36 PM | Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/31/2024
6:46 AM | Takeda Pharmaceutical (Filed by)
Xilio Therapeutics, Inc. (Subject)
| Form SC 13G/A | |
07/31/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2024
6:12 AM | Amakawa Akiko (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:13 AM | Plump Andrew Stewart (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:13 AM | Takeda Pharmaceutical (Subject)
Weber Christophe Pierre (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:14 AM | Shannon Elaine Mary (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
|
07/10/2024
6:15 AM | Ricci Gabriele (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:15 AM | Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:16 AM | Kim Julie So-Young (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:16 AM | Duprey Lauren Rusckowski (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:17 AM | Pignagnoli Agosti Marcello (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:17 AM | Sequeira Ramona (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:18 AM | Bitetti Teresa Marie (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:19 AM | Takeda Pharmaceutical (Subject)
Wozniewski Thomas Otto Claus (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/09/2024
5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/05/2024
10:28 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/02/2024
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/01/2024
5:33 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2024
7:24 AM | Takeda Pharmaceutical (Subject)
| Form FWP | |
06/28/2024
7:25 AM | Takeda Pharmaceutical (Filer)
| Form 424B2
Transaction specifc information for a delayed shelf offering | |
06/27/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 424B5 | |
06/26/2024
7:26 AM | Takeda Pharmaceutical (Filer)
| Form F-3ASR | |
06/26/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/26/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/26/2024
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 20-F
Registration statement / Annual report / Transition report | |
06/17/2024
5:46 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/11/2024
5:23 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/10/2024
5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/07/2024
5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/07/2024
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/03/2024
5:45 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/03/2024
5:26 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024
5:24 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024
5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024
5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024
5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/21/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
War on Elon Escalates… (Ad) A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. |
05/09/2024
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024
5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024
5:08 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/25/2024
5:04 AM | Takeda Pharmaceutical (Filer)
| Form SD
Specialized Disclosure Report | |
04/19/2024
5:12 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/15/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/10/2024
5:10 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
04/01/2024
5:15 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
03/27/2024
5:34 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/09/2024
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/06/2024
8:36 AM | BlackRock Inc. (Filed by)
Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/05/2024
5:24 AM | Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/02/2024
5:16 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024
5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024
5:06 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/25/2024
5:13 AM | Phathom Pharmaceuticals, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:11 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
01/19/2024
5:03 AM | Equillium, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13G | |
01/16/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/14/2023
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/30/2023
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/13/2023
5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/30/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/26/2023
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/26/2023
5:22 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/18/2023
5:21 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/18/2023
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/02/2023
5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/28/2023
5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/11/2023
5:50 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
